All In MedTech

Device Trial Radar · NCT05966961

Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery

'All Comer'/'Real-world' Registry-based Randomized, Prospective, Multicenter Clinical Trial to Evaluate the Incidence of Complications Using Novosyn® CHD Suture Versus Polyglactin 910 Suture to Close the Wound After Emergency or Elective Laparotomy or Laparoscopic Surgery

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,998

Planned (sponsor's estimate)

Start

Sep 18, 2023

Primary completion

Aug 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Aesculap AGNot on our public-company list
Sponsor type
Industry
Collaborators
B.Braun Surgical SA
First posted
Aug 1, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.

Conditions

  • Surgical Site Infection

Interventions

  • Novosyn® in emergency or elective laparotomy or laparoscopic surgeryDevice

    Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

  • Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgeryDevice

    Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of surgical site infection (superficial (A1) and deep (A2)Time frame: until 30 days + 5 days after surgery.

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • Policlinico di Bari

    Bari, Apulia, Italy · Recruiting

  • Pineta Grande Hospital

    Castel Volturno, Campania, Italy · Recruiting

  • Ospedale di Lavagna ASL 4

    Lavagna, Liguria, Italy · Recruiting

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.